Natural history of serum HIV-1 RNA levels in 330 patients with a known date of infection

AIDS

Volumn 14, Issue 2, 2000, Pages 123-131

  Hubert, Jean Baptiste ^a,b   Burgard, Marianne ^c   Dussaix, Elisabeth ^d   Tamalet, Catherine ^e   Deveau, Christiane ^a   Le Chenadec, Jérôme ^a   Chaix, Marie Laure ^c   Marchadier, Eric ^d   Vildé, Jean Louis ^f   Delfraissy, Jean François ^b   Meyer, Laurence ^a   Rouzioux, Christine ^c  

^a Department of Epidemiology ^*  (France)

^b BICÊTRE HOSPITAL   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d HÔPITAL PAUL BROUSSE   (France)

^e TIMONE HOSPITAL   (France)

^f BICHAT HOSPITAL   (France)

Author keywords

Disease progression; HIV 1 infection; Longitudinal HIV 1 RNA levels; Natural history

Indexed keywords

CD4 ANTIGEN; DIDANOSINE; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; COHORT ANALYSIS; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; SEROCONVERSION; SERUM; VIREMIA; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; BLOOD TRANSFUSION; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; REAGENT KITS, DIAGNOSTIC; RNA, VIRAL; SUBSTANCE ABUSE, INTRAVENOUS; TIME FACTORS; VIRAL LOAD;

EID: 0033998626     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200001280-00007     Document Type: Article

References (49)

1. 1. Lee TH, Sheppard HW, Reis M, Dondero D, Osmond D, Busch MP. Circulating HIV-1-infected cell burden from seroconversion to AIDS: importance of postseroconversion viral load on disease course. J Acquired Immune Defic Syndr 1994, 7:381-388.
2. 2. Henrard DR, Darr E, Farzadegan H, et al. Virologic and immunologic characterization of symptomatic and asymptomatic primary HIV-1 infection. J Acquired Immune Defic Syndr 1995, 9:305-310.
3. 3. Mellors JW, Kingsley LA, Rinaldo CR, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995, 122:573-579.
4. 4. Hogervorst E, Jurriaans S, De Wolf F, et al. Predictors for non-and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels. J Infect Dis 1995, 171:811-821.
5. 5. Henrard DR, Phillips JF, Muenz LR, et al. Natural history of HIV-1 cell-free viremia. JAMA 1995, 274:554-558.
6. 6. Katzenstein TL, Pederson C, Nielsen C, Lundgren JD, Jakobsen PH, Cerstoft J. Longitudinal serum HIV RNA quantification: correlation to viral phenotype at seroconversion and clinical outcome. AIDS 1996, 10:167-173.
7. 7. Wong MT, Dolan MJ, Kozlow E, et al. Patterns of virus burden and T cell phenotype are established early and are correlated with the rate of disease progression in human immunodeficiency virus type 1-infected persons. J Infect Dis 1996, 173:877-887.
8. 8. Mellors JW, Rinaldo CR, Phalguni C, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167-1170.
9. 9. O'Brien TR, Blattner WA, Waters D, et al. Serum HIV-1 RNA levels and time to development of AIDS in the multicenter hemophilia cohort study. JAMA 1996, 276:105-110.
10. 10. Farzadegan H, Henrard DR, Kleeberger CA, et al. Virologic and serologic markers of rapid progression to AIDS after HIV-1 seroconversion. J Acquired Immune Defic Syndr 1996, 13: 448-455.
11. 11. O'Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996, 334:426-431.
12. 12. Phillips AN, Eron J, Bartlett J, et al. Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. AIDS 1997, 11:169-175.
13. 13. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
14. 14. Marschner IC, Collier AC, Coombs RW, et al. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis 1998, 177:40-47.
15. 15. Fauci AS. Host factors and the pathogenesis of HIV-induced disease. Nature 1996, 384:529-534.
16. 16. Haynes BF, Pantaleo C, Fauci AS. Toward an understanding of the correlates of protective immunity to HIV infection. Science 1996, 271:324-327.
17. 17. Pachl C, Todd JA, Kern DG, et al. Rapid and precise quantitation of HIV-1 RNA in plasma using a branched DNA signal amplification assay. J Acquired Immune Defic Syndr 1995, 8:446-454.
18. 6/L. AIDS 1997, 11:53-57.
19. 19. Paxton WB, Coombs RW, McElrath MJ, et al. Longitudinal analysis of quantitative virologic measures in human immunodeficiency virus-infected subjects with ≥ 400 CD4 lymphocytes: implications for applying measurements to individual patients. J Infect Dis 1997, 175:247-254.
20. 20. Jurriaans S, Van Gemen B, Weverling GJ, et al. The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course? Virology 1994, 204:223-233.
21. 21. Spijkerman IJB, Prins M, Goudsmit J, et al. Early and late HIV-1 RNA level and its association with other markers and disease progression in long-term AIDS-free homosexual men. AIDS 1997, 11:1383-1388.
22. 22. Michael NL, Chang G, Kim JH, Birx DL. Dynamics of cell-free viral burden in HIV-1-infected patients. J Acquired Immune Defic Syndr 1997, 14:237-242.
23. 23. Keet IPM, Janssen M, Veugelers PJ, et al. Longitudinal analysis of CD4 T cell counts, T cell reactivity, and human immunodeficiency virus type 1 RNA levels in persons remaining AIDS-free despite CD4 cell counts < 200 for > 5 years. J Infect Dis 1997, 176:665-671.
24. 24. de Wolf F, Spijkerman I, Schellekens PT, et al. AIDS prognosis based on HIV-1 RNA, CD4+ T-cell count and function: markers with reciprocal predictive value over time after seroconversion. AIDS 1997, 11:1799-1806.
25. 25. O'Brien TR, Rosenberg PS, Yellin F, Goedert JJ. Longitudinal HIV-1 RNA levels in a cohort of homosexual men. J Acquired Immune Defic Syndr 1998, 18:155-161.
26. 26. Bucquet D, Deveau C, Belanger F, et al. Cohorte française multicentrique d'adultes infectés par le VIH. Description et évolution après 4 ans de suivi. Presse Med 1994, 23:1247-1251.
27. 27. Carré C, Deveau C, Belanger F, et al. Effect of age and exposure group on the onset of AIDS in heterosexual and homosexual HIV-infected patients. AIDS 1994, 8:797-802.
28. M serotypes in french blood donors over a 10-year period (1985-1995). AIDS 1997, 11:1503-1508.
29. 29. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol 1994, 32:292-300.
30. 30. Diggle PJ, Liang KY, Zeger SL. Fitting smooth curves to longitudinal data. In: Analysis of longitudinal data. Atkinson AC, Copas JB, Pierce DA, Schervish MJ, Titterington DM (editors). Oxford: Oxford University Press; 1994. pp. 41-47.
31. 31. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996, 335:1091-1098.
32. 32. Raffi F, Reliquet V, Auger S, et al. Efficacy and safety of stavudine and didanosine combination therapy in antiretroviral-experienced patients. AIDS 1998, 12:1999-2005.
33. 33. Delta Coordinating Committee and Delta Virology Committee. HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: an extended virology study. AIDS 1999, 13:57-65.
34. 34. Schockmel GA, Yerly S, Perrin L. Detection of low HIV-1 RNA levels in plasma. J Acquired Immune Defic Syndr 1997, 14: 179-183.
35. 35. Craib KJP, Strathdee SA, Hogg RS, et al. Serum levels of human immunodeficiency virus type 1 (HIV-1) RNA after seroconversion: a predictor of long-term mortality in HIV infection, J Infect Dis 1997, 176:798-800.
36. 36. Lefrère JJ, Roudot-Thoroval F, Mariotti M, et al. The risk of disease progression is determined during the first year of human immunodeficiency virus type 1 infection. J Infect Dis 1998, 177:1541-1548.
37. 37. Mellors JW, Muñoz A, Ciorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997, 126:946-954.
38. 38. Feng Y, Broder C, Kennedy P, Berger E. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996, 272:872-877.
39. 39. Bratt G, Sandström E, Albert J, Samson M, Wahren B. The influence of MT-2 tropism on the prognostic implications of the D△32 deletion in the CCR-5 gene. AIDS 1997, 11:1415-1419.
40. 40. Koot M, Keet IPM, Vos AHV, et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993, 118:681-688.
41. 41. Spijkerman IJB, de Wolf F, Langendam MW, Schuitemaker H, Coutinho RA. Emergence of syncytium-inducing HIV-1 variants coincides with burst in viral RNA level and is an independent predictor for progression to AIDS. Vth Conference on Retroviruses and Opportunistic Infections, Chicago, February 1998 [Abstract 66].
42. 42. Glushakova S, Grivel JC, Fitzgerald W, Sylwester A, Zimmerberg J, Margolis LB. Evidence for the HIV-1 phenotype switch as a causal factor in acquired immunodeficiency. Nat Med 1998, 4:346-349.
43. 43. Scarlatti G, Tresoldi E, Björndal A, et al. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med 1997, 11:1259-1265.
44. 44. Schacker T, Hughes J, Shea T, Coombs R, Corey L. Biological and virological characteristics of primary HIV infection. Ann Intern Med 1998, 128:613-620.
45. 45. Daar ES, Moudgil T, Meyer RD, Ho DD. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med 1991, 324:961-964.
46. 46. Clark SJ, Saag MS, Decker WD, et al. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med 1991, 324:954-960.
47. 47. Piatak M, Saag MS, Yang LC, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993, 259:1749-1754.
48. 48. Kinloch-De-Loés S, Hirschel BJ, Hoen B, et al. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 1995, 333:408-413.
49. 49. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997, 278:1447-1450.